EP1188747A1 — Phenoxypropylamine compounds
Assigned to Tanabe Pharma Corp · Expires 2002-03-20 · 24y expired
What this patent protects
The present invention relates to a phenoxypropylamine compound of the formula (I) <CHEM> wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously sho…
USPTO Abstract
The present invention relates to a phenoxypropylamine compound of the formula (I) <CHEM> wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.